Xingsheng Hu

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

Yuankai Shi, Xingsheng Hu, Shucai Zhang et al. · The Lancet Respiratory Medicine · 2021 · 115 citations

Genetic Analysis, Egfr T790m, Phase 2B +12

Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation

Yuankai Shi, Shucai Zhang, Xingsheng Hu et al. · Journal of Thoracic Oncology · 2020 · 103 citations · Full text

Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer

Hui Xia, Xingyang Xue, Huaxin Ding et al. · Clinical Lung Cancer · 2019 · 91 citations

Oncology, Ntrk1 Fusion, Medicine +8

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

Yuxin Mu, Xuezhi Hao, Puyuan Xing et al. · Journal of Cancer Research and Clinical Oncology · 2020 · 63 citations · Full text

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

Shun Lü, Jianying Zhou, Hong Jian et al. · The Lancet Respiratory Medicine · 2023 · 63 citations

First-line Therapy, Medicine, Randomised Phase 3 +8